Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth Amidst Competitive Challenges
12:03am, Wednesday, 11'th Feb 2026
Total Product Sales (Q4 2025): $7.9 billion, up 5% year over year.Total Product Sales (Full Year 2025): $28.9 billion, up 1% from 2024.HIV Sales (Q4 2025): $5.
Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
09:14pm, Tuesday, 10'th Feb 2026
Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
07:31pm, Tuesday, 10'th Feb 2026
While the top- and bottom-line numbers for Gilead (GILD) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare
Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates
06:11pm, Tuesday, 10'th Feb 2026
Gilead Sciences (GILD) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate of $1.83 per share. This compares to earnings of $1.9 per share a year ago.
Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance
05:56pm, Tuesday, 10'th Feb 2026
Gilead Sciences Inc. (NASDAQ: GILD) shares slipped in Tuesday's extended trading after the company released its fourth-quarter earnings report with weak fiscal 2026 guidance.
Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
04:39pm, Tuesday, 10'th Feb 2026
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
Gilead quarterly results beat Wall Street estimates
04:07pm, Tuesday, 10'th Feb 2026
Gilead Sciences on Tuesday reported fourth-quarter sales and profit that came in slightly above Wall Street estimates, while its 2026 financial forecast was at the lower end of analysts' expectations.
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
04:02pm, Tuesday, 10'th Feb 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Dividend--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 3.8% in the company's quarterly
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
04:01pm, Tuesday, 10'th Feb 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025. “Our fourth quarter and fu
First Look: Novo sues Hims, BP halts buybacks, Meta faces trial
07:39am, Tuesday, 10'th Feb 2026
Stock News Novo sues Hims over compounded weight-loss drugs: Novo Nordisk (NVO) filed suit to stop Hims and Hers Health (HIMS) from selling compounded semaglutide
Gilead Sciences: Buy This Stock For Both Dividend And Growth
05:45am, Tuesday, 10'th Feb 2026
I rate Gilead Sciences (GILD) a 'Buy' with a $191 price target. It offers an attractive 2.1% dividend yield and low volatility. GILD's revenue is anchored by Biktarvy, protected by exclusivity through
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD
08:16pm, Monday, 09'th Feb 2026
With their Q4 results approaching after-market hours on Tuesday, February 10, Exelixis (EXEL) and Gilead Sciences (GILD) are two top-performing medical stocks to consider.
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
12:41pm, Monday, 09'th Feb 2026
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Should You Buy Gilead Sciences Before Feb. 10?
09:44am, Monday, 09'th Feb 2026
Gilead Sciences' recent quarterly updates have been better than what the market expected. The company's results could improve with newer launches.
First Look: Amazon's $200B Capex, Coinbase's SB Ad, Kroger CEO
07:38am, Monday, 09'th Feb 2026
Stock News Japan rally on election landslide: Japanese stocks hit record highs after Prime Minister Sanae Takaichi's coalition secured a two-thirds lower-house
